Literature DB >> 9428647

Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides.

A Amici1, M Emanuelli, G Magni, N Raffaelli, S Ruggieri.   

Abstract

Two cytoplasmic forms of pyrimidine nucleotidase (PN-I and PN-II) have been purified from human erythrocytes to apparent homogeneity and partially characterized. They preferentially hydrolyse pyrimidine 5'-monophosphates and 3'-monophosphates respectively. PN-I and PN-II operate as interconverting activities, capable of transferring the phosphate from the pyrimidine nucleoside monophosphate donor(s) to various nucleoside acceptors, including important drugs like 3'-azido-3'-deoxy-thymidine (AZT), cytosine-beta-D-arabinofuranoside (AraC) and 5-fluoro-2'-deoxy-uridine (5FdUrd), pyrimidine analogues widely used in chemotherapy. Kinetic analysis showed linear behaviour for both PN-I and PN-II. PN-I phosphotransferase activity revealed higher affinity for oxynucleosides with respect to deoxy-nucleosides, whereas the contrary seems to be true for PN-II. These results show for the first time that soluble pyrimidine nucleotidases are endowed with pyrimidine-specific phosphotransferase activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428647     DOI: 10.1016/s0014-5793(97)01464-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

Review 1.  Structures of proteins of biomedical interest from the Center for Eukaryotic Structural Genomics.

Authors:  George N Phillips; Brian G Fox; John L Markley; Brian F Volkman; Euiyoung Bae; Eduard Bitto; Craig A Bingman; Ronnie O Frederick; Jason G McCoy; Betsy L Lytle; Brad S Pierce; Jikui Song; Simon N Twigger
Journal:  J Struct Funct Genomics       Date:  2007-09-06

2.  Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

Authors:  Amit K Mitra; Kristine R Crews; Stanley Pounds; Xueyuan Cao; Tanya Feldberg; Yogita Ghodke; Varsha Gandhi; William Plunkett; M Eileen Dolan; Christine Hartford; Susana Raimondi; Dario Campana; James Downing; Jeffrey E Rubnitz; Raul C Ribeiro; Jatinder K Lamba
Journal:  J Pharmacol Exp Ther       Date:  2011-06-28       Impact factor: 4.030

3.  The Chlamydia psittaci genome: a comparative analysis of intracellular pathogens.

Authors:  Anja Voigt; Gerhard Schöfl; Hans Peter Saluz
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

4.  The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

Authors:  I Hubeek; R W Stam; G J Peters; R Broekhuizen; J P P Meijerink; E R van Wering; B E S Gibson; U Creutzig; C M Zwaan; J Cloos; D J Kuik; R Pieters; G J L Kaspers
Journal:  Br J Cancer       Date:  2005-12-12       Impact factor: 7.640

5.  Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.

Authors:  May Levin; Michal Stark; Yishai Ofran; Yehuda G Assaraf
Journal:  Cancer Cell Int       Date:  2021-01-14       Impact factor: 5.722

6.  Novel homozygous nonsense mutation in the P5'N-1 coding gene as an alternative cause for hereditary anemia with basophilic stippling.

Authors:  Martin Kirschner; Inga Rebecca Heinen; Steffen Koschmieder; Licinio Manco; Celeste Bento; Thomas Eggermann; Ingo Kurth; Edgar Jost; Tim H Brümmendorf; Roland Fuchs
Journal:  Clin Case Rep       Date:  2022-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.